Copyright © 1990 by the European Society of Cardiology.
© 1990 The European Society of Cardiology
A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction
Section of Coagulation and Fibrinoloysis, Department of Clinical Chemistry and the Department of Internal Medicine, Ribe County Hospital, Esbjerg and Section of Thrombosis Research, South Jutland University Centre Esbjerg, Denmark
Received 15 May 1989; revised 13 October 1989; .
Correspondence to: Steffen Munkvad, MD, section of Clinical Chemistry, Ribe Country hospital in Esbjerg. DK-Esbjerg, Denmark.
Abstract
The balance between the coagulation system generating fibrin and its subsequent removal by the fibrinolytic system determines the fate of fibrin deposited in the vascular system. In a prospective study, selected haemostatic variables assessing this balance were determined in plasma samples from 20 consecutive patients admitted with unstable angina pectoris. Over a follow-up period of 6 years, eight patients developed myocardial infarction, whereas 12 patients did not. There was no significant difference between the two groups in the median plasma concentrations of thrombin-antithrombin HI complexes reflecting the coagulant activity. The infarction group was characterized by a significantly lower median activity of tissue plasminogen activator in plasma euglobulins (P<0.05), a higher median concentration of tissue plasminogen activator antigen in plasma (P <0.05) and a tendency to higher plasma levels of antigenic and functional plasminogen activator inhibition. In all patients, the activities of tissue plasminogen activator inhibitor and of tissue plasminogen activator were significantly associated (rs= —0.4811, P<0.05). We conclude that a depressed fibrinolytic capacity attributable to a low tissue plasminogen activator activity is of pathogenetic importance for the development of myocardial infarction in patients with unstable angina pectoris.
Key Words: Unstable angina pectoris • tissue-type plasminogen activator • myocardial infarction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G.D.O. Lowe, J. Danesh, S. Lewington, M. Walker, L. Lennon, A. Thomson, A. Rumley, and P.H. Whincup Tissue plasminogen activator antigen and coronary heart disease: Prospective study and meta-analysis Eur. Heart J., February 1, 2004; 25(3): 252 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Bertrand, M. L. Simoons, K. A.A. Fox, L. C. Wallentin, C. W. Hamm, E. McFadden, P. J. De Feyter, G. Specchia, and W. Ruzyllo Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Eur. Heart J., December 1, 2002; 23(23): 1809 - 1840. [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Witherow, P. Dawson, C. A. Ludlam, K. A. A. Fox, and D. E. Newby Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy J. Am. Coll. Cardiol., September 4, 2002; 40(5): 961 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Labinjoh, D. E. Newby, M. P. Pellegrini, N. R. Johnston, N. A. Boon, and D. J. Webb Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition J. Am. Coll. Cardiol., November 1, 2001; 38(5): 1402 - 1408. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.E Bertrand, M.L Simoons, K.A.A Fox, L.C Wallentin, C.W Hamm, E McFadden, P.J de Feyter, G Specchia, and W Ruzyllo Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology: Recommendations of the Task Force of the European Society of Cardiology Eur. Heart J., September 1, 2000; 21(17): 1406 - 1432. [PDF]
|
|
|
|
|
|
J. L. Anderson, J. B. Muhlestein, J. Habashi, J. F. Carlquist, T. L. Bair, S. P. Elmer, and B. P. Davis Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction J. Am. Coll. Cardiol., November 15, 1999; 34(6): 1778 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cesari and G. P. Rossi Plasminogen Activator Inhibitor Type 1 in Ischemic Cardiomyopathy Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1378 - 1386. [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Grundy, G. J. Balady, M. H. Criqui, G. Fletcher, P. Greenland, L. F. Hiratzka, N. Houston-Miller, P. Kris-Etherton, H. M. Krumholz, J. LaRosa, et al. Primary Prevention of Coronary Heart Disease: Guidance From Framingham : A Statement for Healthcare Professionals From the AHA Task Force on Risk Reduction Circulation, May 19, 1998; 97(18): 1876 - 1887. [Full Text] [PDF]
|
|
|
|
|
|
M. Cigolini, G. Targher, I.A. B. Andreis, M. Tonoli, G. Agostino, and G. De Sandre Visceral Fat Accumulation and Its Relation to Plasma Hemostatic Factors in Healthy Men Arterioscler. Thromb. Vasc. Biol., March 1, 1996; 16(3): 368 - 374. [Abstract] [Full Text]
|
|
|
|
|
|
W. L. Chandler, W. C. Levy, and J. R. Stratton The Circulatory Regulation of TPA and UPA Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol and Phenylephrine Circulation, November 15, 1995; 92(10): 2984 - 2994. [Abstract] [Full Text]
|
|
|
|
|
|
T. Padro, J. J. Emeis, M. Steins, K. W. Schmid, and J. Kienast Quantification of Plasminogen Activators and Their Inhibitors in the Aortic Vessel Wall in Relation to the Presence and Severity of Atherosclerotic Disease Arterioscler. Thromb. Vasc. Biol., July 1, 1995; 15(7): 893 - 902. [Abstract] [Full Text]
|
|
|
|
|
|
H. M. Hoffmeister, M. Jur, H. P. Wendel, W. Heller, and L. Seipel Alterations of Coagulation and Fibrinolytic and Kallikrein-Kinin Systems in the Acute and Postacute Phases in Patients With Unstable Angina Pectoris Circulation, May 15, 1995; 91(10): 2520 - 2527. [Abstract] [Full Text]
|
|